Open AccessBaseline use of angiotensin-converting enzyme inhibitor/AT1 blocker and outcomes in hospitalized coronavirus disease 2019 African-American patients
Author(s) -
Priyank Shah,
Jack Owens,
James Franklin,
Yash Jani,
Ashish Kumar,
Rajkumar Doshi
Publication year - 2020
Publication title -
journal of hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.249
H-Index - 172
eISSN - 1473-5598
pISSN - 0263-6352
DOI - 10.1097/hjh.0000000000002584
Subject(s) - medicine , ace inhibitor , angiotensin converting enzyme , coronavirus , covid-19 , angiotensin ii receptor type 1 , disease , african american , angiotensin receptor , angiotensin ii , virology , blood pressure , infectious disease (medical specialty) , history , ethnology , outbreak
The primary objective of this study is to determine the effect of baseline use of angiotensin-converting enzyme inhibitor (ACE-i)/AT1 blocker (ARB) on mortality in hospitalized coronavirus disease 2019 (Covid-19) African-American patients. The secondary objectives are, to determine the effect of baseline use of ACE-i/ARB on the need for mechanical ventilation, new dialysis, ICU care, and on composite of above-mentioned outcomes in the same cohort.